Compare Abbott Laboratories (ABT) vs Royal Bank of Canada (RY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Royal Bank of Canada — how do they compare? Abbott Laboratories trades at $95.65 (market cap $166.94B), while Royal Bank of Canada trades at $205.8 (market cap $290.60B). The key difference: Royal Bank of Canada is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | RY | |
|---|---|---|
Market Cap | $166.94B | $290.60B |
Sector | Health | Financials |
52-Week High | $136.62 | $209.07 |
52-Week Low | $82.57 | $128.46 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Royal Bank of Canada (RY) trades at $209.07, up 2.09% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 31.85% net income margin and 17.17% ROE, supported by a $1.76 quarterly dividend and a share repurchase program. Revenue grew to $66.53B in 2025, and cash flow trends indicate improving operational strength.
RY presents a solid investment case with consistent profitability and shareholder returns, though valuation metrics like a P/E of 19.2 and P/B of 3.17 suggest premium pricing. Risks include economic sensitivity and high debt levels, but analyst consensus leans positive with 43% buy ratings. The outlook remains favorable if earnings growth persists amid macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
